Sanuwave (OTC: SNWV) swings to loss and withdraws its 2026 outlook
Rhea-AI Filing Summary
Sanuwave Health reported Q2 2026 results with softer revenue and earnings. Revenue was $9.7 million, down 3% from $10.1 million, and gross margin was 76.2% versus 78.1% a year earlier. Ultramist system sales declined to 82 units from 116, while Ultramist applicator revenue grew 13% to $7.3 million, accounting for roughly three-quarters of total revenue.
The business shifted from profit to loss: Q2 operating loss was $0.3 million versus $1.4 million income, and net loss was $0.7 million versus $0.6 million income in Q2 2025. Adjusted EBITDA fell to $1.2 million from $3.2 million. Management highlighted a challenging advanced wound care market, CMS reimbursement changes, and a growing secondary market for used Ultramist systems as pressures on new system sales. In light of Medicare reimbursement developments and a CMS proposed rule for 2027 code 97610, Sanuwave withdrew its 2026 guidance and does not plan to provide new guidance until after CMS issues its final rule, anticipated in the fourth quarter of 2026.
Positive
- None.
Negative
- Fiscal 2026 guidance withdrawn owing to Medicare reimbursement developments and CMS’s proposed 2027 rule for code 97610, reducing visibility into future performance.
- Profitability deteriorated from Q2 2025 net income of $0.6 million to a Q2 2026 net loss of $0.7 million, with Adjusted EBITDA falling from $3.2 million to $1.2 million.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Q2 2026 Revenue: $9.7 million
Q2 2026 Gross Margin: 76.2%
Q2 2026 Net (Loss) Income: $(0.7) million
+5 more
8 metrics
Q2 2026 Revenue
$9.7 million
Three months ended June 30, 2026; down 3% from $10.1 million in Q2 2025
Q2 2026 Gross Margin
76.2%
Gross margin percentage for the three months ended June 30, 2026
Q2 2026 Net (Loss) Income
$(0.7) million
Net loss for the second quarter of 2026 versus $0.6 million income in Q2 2025
Q2 2026 Adjusted EBITDA
$1.2 million
Adjusted EBITDA for the three months ended June 30, 2026 versus $3.2 million in Q2 2025
Ultramist Systems Sold Q2 2026
82 units
Ultramist systems sold in Q2 2026; down from 116 in Q2 2025
Ultramist Applicator Revenue Q2 2026
$7.3 million
Applicator revenue in Q2 2026; up 13% from $6.4 million in Q2 2025
Cash and Cash Equivalents
$9.4 million
Cash and cash equivalents as of June 30, 2026
Total Liabilities
$33.8 million
Total liabilities as of June 30, 2026 versus $35.7 million at December 31, 2025
Key Terms
Adjusted EBITDA, CMS proposed rule, secondary market for used Ultramist systems, right-of-use (ROU) leases, +1 more
5 terms
Adjusted EBITDA financial
"Adjusted EBITDA [1] for the three months ended June 30, 2026"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
CMS proposed rule regulatory
"Moving on to the CMS proposed rule for 2027 97610 reimbursement"
A CMS proposed rule is a draft regulation issued by the U.S. Centers for Medicare & Medicaid Services that outlines planned changes to how government health programs pay providers, cover treatments, or collect data. Think of it as a policy blueprint open for public comment before it becomes binding; investors watch these proposals because they can change reimbursement rates, market access, compliance costs, and revenue prospects for healthcare companies and insurers.
secondary market for used Ultramist systems market
"the emergence of a significant market for used Ultramist systems"
right-of-use (ROU) leases financial
"Depreciation and amortization excludes amortization of right-of-use (ROU) leases"
contract liabilities financial
"Current portion of contract liabilities and contract liabilities, less current portion"
Contract liabilities are amounts a company has been paid in advance for goods or services it still owes to customers — think of them like gift cards or prepaid subscriptions the company must fulfill later. For investors, they show promised future work or deliveries that will turn into revenue over time, reveal cash already collected, and help assess whether a firm has a backlog of obligations that could affect future earnings and cash flow.
Earnings Snapshot
Revenue: $9.7 million · Guidance included
Quarter ended June 30, 2026
Revenue
$9.7 million
Down 3% from $10.1 million in Q2 2025
Gross Margin
76.2%
Compared with 78.1% in Q2 2025
Net (Loss) Income
$(0.7) million
Versus net income of $0.6 million in Q2 2025
Adjusted EBITDA
$1.2 million
Versus Adjusted EBITDA of $3.2 million in Q2 2025
Guidance
Previously issued fiscal year 2026 guidance has been withdrawn; no new quarterly or annual guidance will be provided until after CMS issues its final rule, anticipated in the fourth quarter of 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did Sanuwave (SNWV) perform financially in Q2 2026?
Sanuwave reported Q2 2026 revenue of $9.7 million, down 3% from $10.1 million in Q2 2025 and a net loss of $0.7 million versus net income of $0.6 million a year earlier, reflecting weaker profitability.
What were Ultramist system and applicator trends for SNWV in Q2 2026?
Sanuwave sold 82 Ultramist systems in Q2 2026, down from 116 a year earlier, while Ultramist applicator revenue rose 13% to $7.3 million. Applicators represented about 75% of quarterly revenue, above the company’s 60–65% target range.
What happened to Sanuwave’s margins and earnings in Q2 2026?
Gross margin was 76.2% in Q2 2026, down from 78.1% in Q2 2025. The company posted an operating loss of $0.3 million and a net loss of $0.7 million, compared with operating income of $1.4 million and net income of $0.6 million a year earlier.
Did Sanuwave (SNWV) change its 2026 outlook in this report?
Yes. Sanuwave withdrew its previously issued fiscal 2026 guidance due to market conditions, including Medicare reimbursement developments. The company will not provide new quarterly or annual guidance until after CMS issues its final rule, expected in Q4 2026.
How are CMS reimbursement and regulatory changes affecting Sanuwave?
Management cited CMS reimbursement changes, recoupments, and a proposed 2027 rule for code 97610 as headwinds, contributing to customer stress and weaker new system sales. Sanuwave plans to participate actively in the CMS comment period seeking reconsideration before the final rule.
What is Sanuwave’s liquidity and balance sheet position as of June 30, 2026?
As of June 30, 2026, Sanuwave held $9.4 million in cash and cash equivalents. Total assets were $36.6 million, with total liabilities of $33.8 million and stockholders’ equity of $2.8 million, indicating a highly leveraged capital structure.
1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported) | |||||
| (Exact name of registrant as specified in its charter) | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of principal executive offices) | (Zip Code) | ||||||||||
| Registrant’s telephone number, including area code | ||||||||
| N/A | ||
| (Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Common stock, par value $0.001 per share | SNWV | The Nasdaq Stock Market LLC | ||||||
Indicate by check mark whether the registration is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
1
2
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, Sanuwave Health, Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the second quarter ended June 30, 2026. As previously announced, a business update via conference call will occur on August 7, 2026 at 8:30 am EST. Materials are provided on the Company’s website at www.sanuwave.com/investors.
The information in this Item 2.02 of this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No. | Description | |||||||
99.1 | Press Release dated | |||||||
| 104 | Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. | |||||||
2
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SANUWAVE HEALTH, INC. | ||||||||
Dated: | By: | /s/ Peter Sorensen | ||||||
| Name: | Peter Sorensen | |||||||
| Title: | Chief Financial Officer | |||||||
3
Exhibit 99.1
Sanuwave Announces Q2 FY2026 Financial Results
Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025.
Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025.
GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 2025.
EDEN PRAIRIE, MN, August 6, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-cleared wound care products, is pleased to provide its financial results for the three months ended June 30, 2026.
Quarter ended June 30, 2026
•Revenue for the three months ended June 30, 2026, totaled $9.7 million, an decrease of 3%, as compared to $10.1 million for the same period of 2025. Revenue for the three months ended June 30, 2026 was slightly above the high end of the revised guidance provided on June 16, 2026.
•82 Ultramist® systems were sold in Q2 2026 down from 116 in Q2 2025, and from 97 in Q1 2026.
•Ultramist® applicator revenue increased by 13% to $7.3 million in Q2 2026, versus $6.4 million for the same quarter last year.
•Gross margin as a percentage of revenue amounted to 76.2% for the three months ended June 30, 2026, versus 78.1% for the same period last year.
•For the three months ended June 30, 2026, operating (loss) income totaled $(0.3) million, compared to $1.4 million in Q2 2025.
•Net loss for the second quarter of 2026 was $0.7 million. This compares to net income of $0.6 million in the second quarter of 2025.
•Adjusted EBITDA [1] for the three months ended June 30, 2026, was $1.2 million versus Adjusted EBITDA of $3.2 million for the same period last year.
“2026 has been a challenging period for the advanced wound care market,” said Morgan Frank, CEO. “Despite this, Q2 was another all time record for Ultramist applicator unit volumes, which increased 13% sequentially from Q1 and 27% year on year. We take this to be a strong sign of ongoing demand for and confidence in the Ultramist system as a treatment modality for complex and non-healing wounds. As previously discussed, system sales were negatively impacted in the quarter both by ongoing stress in our customer base from CMS reimbursement changes and recoupments around allografts and by the emergence of a significant market for used Ultramist systems, which led to lower than expected sales by the Company. As a result, applicator sales accounted for approximately 75% of revenues in the quarter, a number above our target range of 60-65%. The silver lining on that seems to be that demand for systems during the quarter remained fairly robust if one includes our estimation of used sales on top of those sold by the Company. Moving on to the CMS proposed
rule for 2027 97610 reimbursement announced this July, obviously, this is neither what we were hoping for nor what we expected, especially in light of having just had a 14% increase in our proposed reimbursement rate in the HOPD setting come out a couple of weeks prior. While Sanuwave wholeheartedly supports CMS’s goal of accurate, data driven payment, we have some material disagreements with the methodology, process, and assumptions utilized by CMS in their proposed rule for 2027 and, as one might expect, will be active in the comment period to seek reconsideration before a final rule is issued. Our goal in this comment period will be to ensure that the data that drives this decision is both accurate and complete and that it reflects the full practitioner costs (and the systemic benefits) of providing treatment under 97610, which is, of course, the intent of these rules. We believe that we have a strong case to make and, with the support of a great many customers and academic institutions and thought leaders who have reached out with gracious offers to help, we plan to make it vigorously.”
Certain percentages presented in this earnings release are calculated from the underlying whole-dollar amounts and therefore may not recalculate from the rounded numbers used for disclosure purposes.
Financial Outlook
Owing to market conditions including the Medicare reimbursement developments discussed above, Sanuwave is withdrawing its previously issued fiscal year 2026 guidance which should no longer be relied upon. The Company will not provide quarterly or annual guidance until there is greater clarity on these topics and expects to reassess after CMS publishes its final rule which is anticipated in the fourth quarter of 2026.
As previously announced, a business update will occur via conference call on August 7, 2026 at 8:30 a.m. EST. Materials for the conference call are included on the Company’s website at http://www.sanuwave.com/investors.
Telephone access to the call will be available by dialing the following numbers:
Toll Free:1-800-274-8461
Toll/International: 1-203-518-9814
Conference ID: SANUWAVE
OR use the link for instant telephone access to the event.
https://viavid.webcasts.com/starthere.jsp?ei=1771327&tp_key=110b588de5
A replay will be made available through August 21, 2026:
Toll-Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Access ID: 11162356
[1] This is a non-GAAP financial measure. Refer to “Non-GAAP Financial Measures” and the reconciliations in this release for further information.
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates helps restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Non-GAAP Financial Measures
This press release includes certain financial measures that are not presented in our financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). These financial measures are considered "non-GAAP financial measures" and are intended to supplement, and should not be considered as superior to, or a replacement for, financial measures presented in accordance with U.S. GAAP.
The Company uses Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) and Adjusted EBITDA to assess its operating performance. Adjusted EBITDA is Earnings before Interest, Taxes, Depreciation and Amortization adjusted for the change in fair value of derivatives and any significant non-cash or infrequent charges. EBITDA and Adjusted EBITDA should not be considered as alternatives to net income (loss), as a measure of financial performance or any other performance measure derived in accordance with U.S. GAAP, and they should not be construed as an inference that the Company’s future results will be unaffected by unusual or infrequent items. These non-GAAP financial measures are presented in a consistent manner for each period, unless otherwise disclosed. The Company uses these measures for the purpose of evaluating its historical and prospective financial performance, as well as its performance relative to competitors. These measures also help the Company to make operational and strategic decisions. The Company believes that providing this information to investors, in addition to U.S. GAAP measures, allows them to see the Company’s results through the eyes of management, and to better understand its historical and future financial performance. These non-GAAP financial measures are also frequently used by analysts, investors, and other interested parties to evaluate companies in our industry, when considered alongside other U.S. GAAP measures.
EBITDA, Adjusted EBITDA, Adjusted Gross Margin Percentage and Adjusted Operating Income have their limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of the Company’s results as reported under U.S. GAAP. For example, some of these limitations are that EBITDA and Adjusted EBITDA:
•Do not reflect every expenditure, future requirements for capital expenditures or contractual commitments.
•Do not reflect all changes in our working capital needs.
•Do not reflect interest expense, or the amount necessary to service our outstanding debt.
As presented in the U.S. GAAP to Non-GAAP Reconciliations section below, the Company’s non-GAAP financial measures exclude the impact of certain charges that contribute to our net income (loss).
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are: reductions, clawbacks, or recoupments of CMS reimbursement for skin substitutes, allografts, or other advanced wound care products, and their effect on customer behavior and capital budgets; the financial distress, closure, or liquidation of wound care practices and the resulting impact on demand for the Company's systems; the emergence and growth of a secondary market for used Ultramist systems and the cannibalizing effect of such resales on sales of new systems; the Company's ability to qualify, train, and support new users acquiring systems through the secondary market, and the related regulatory, quality, and product-liability considerations; the Company's ability to sustain applicator and consumable volumes and convert system placements into recurring consumable revenue; risks associated with regulatory oversight; the Company's ability to manage its capital resources; competition; and the other factors discussed in detail in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
SELECTED FINANCIAL DATA
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 AND 2025
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||||||||
| Revenue | $ | 9,739 | $ | 10,054 | $ | 19,358 | $ | 19,387 | |||||||||||||||||||||
| Cost of Revenues | 2,315 | 2,206 | 4,502 | 4,164 | |||||||||||||||||||||||||
| Gross Margin | 7,424 | 7,848 | 14,856 | 15,223 | |||||||||||||||||||||||||
| Gross Margin % | 76.2 | % | 78.1 | % | 76.7 | % | 78.5 | % | |||||||||||||||||||||
| Total operating expenses | 7,704 | 6,410 | 16,260 | 13,184 | |||||||||||||||||||||||||
| Operating (Loss) Income | $ | (280) | $ | 1,438 | $ | (1,404) | $ | 2,039 | |||||||||||||||||||||
| Total other expense | (396) | (887) | (711) | (7,606) | |||||||||||||||||||||||||
| Net (Loss) Income | $ | (682) | $ | 551 | $ | (2,121) | $ | (5,567) | |||||||||||||||||||||
NON-GAAP ADJUSTED EBITDA
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| (in thousands) | 2026 | 2025 | 2026 | 2025 | |||||||||||||||||||
| Net (Loss) Income | $ | (682) | $ | 551 | $ | (2,121) | $ | (5,567) | |||||||||||||||
| Non-GAAP Adjustments: | |||||||||||||||||||||||
| Interest expense | 518 | 1,939 | 1,064 | 3,848 | |||||||||||||||||||
Depreciation and amortization 1 | 313 | 226 | 607 | 493 | |||||||||||||||||||
| EBITDA | 149 | 2,716 | (450) | (1,226) | |||||||||||||||||||
| Non-GAAP Adjustments for Adjusted EBITDA: | |||||||||||||||||||||||
| Change in fair value of derivative liabilities | - | (990) | - | 3,911 | |||||||||||||||||||
| Other non-cash or infrequent charges: | |||||||||||||||||||||||
| Stock-based compensation | 1,572 | 1,132 | 3,143 | 2,116 | |||||||||||||||||||
State & local sales tax 2 | (532) | 329 | (194) | 705 | |||||||||||||||||||
| Sale of excess inventory | - | - | (220) | - | |||||||||||||||||||
| Adjusted EBITDA | $ | 1,189 | $ | 3,188 | $ | 2,279 | $ | 5,506 | |||||||||||||||
1 Depreciation and amortization excludes amortization of right-of-use (ROU) leases. Prior period amounts have been retroactively revised to conform to this presentation. This change had no effect on previously reported GAAP results.
2 The charges represent a non-recurring state and local sales tax expense related to the restatement of prior period financial statements.
CONDENSED CONSOLIDATED BALANCE SHEETS
| June 30, 2026 | December 31, 2025 | ||||||||||
| ASSETS | |||||||||||
| Current Assets: | |||||||||||
| Cash and cash equivalents | $ | 9,376 | $ | 11,959 | |||||||
Accounts receivable, net of allowance of $1,617 and $1,265, respectively | 5,801 | 5,422 | |||||||||
| Inventory | 7,070 | 5,934 | |||||||||
| Prepaid expenses and other current assets | 954 | 1,312 | |||||||||
| Total Current Assets | 23,201 | 24,627 | |||||||||
| Non-Current Assets: | |||||||||||
| Property and equipment, net | 2,255 | 1,972 | |||||||||
| Right of use assets, net | 953 | 390 | |||||||||
| Intangible assets, net | 2,887 | 3,026 | |||||||||
| Goodwill | 7,260 | 7,260 | |||||||||
| Secured revolving credit facility debt issuance costs, net | 49 | 68 | |||||||||
| Total Non-current Assets | 13,404 | 12,716 | |||||||||
| Total Assets | $ | 36,605 | $ | 37,343 | |||||||
| LIABILITIES | |||||||||||
| Current Liabilities: | |||||||||||
| Current portion of secured term loan, net of debt issuance costs | $ | 5,599 | $ | 5,638 | |||||||
| Accounts payable | 3,308 | 3,251 | |||||||||
| Accrued expenses | 8,605 | 8,382 | |||||||||
| Current portion of operating lease liabilities | 5 | 157 | |||||||||
| Current portion of contract liabilities | 632 | 388 | |||||||||
| Accrued interest | 17 | 24 | |||||||||
| Other | 7 | 7 | |||||||||
| Total Current Liabilities | 18,173 | 17,847 | |||||||||
| Non-current Liabilities: | |||||||||||
| Secured term loan, net of current portion and debt issuance costs | 12,922 | 15,667 | |||||||||
| Secured revolving credit facility | 655 | 655 | |||||||||
| Operating lease liabilities, less current portion | 1,525 | 854 | |||||||||
| Contract liabilities, less current portion | 543 | 701 | |||||||||
| Total Non-current Liabilities | 15,645 | 17,877 | |||||||||
| Total Liabilities | $ | 33,818 | $ | 35,724 | |||||||
| STOCKHOLDERS’ EQUITY | |||||||||||
Preferred Stock, par value $0.001, 5,000,000 shares authorized; 6,175 shares Series A, 293 shares Series B, 90 shares Series C and 8 shares Series D designated, respectively; no shares issued and outstanding at June 30, 2026 and December 31, 2025 | $ | - | $ | - | |||||||
Common stock, par value $0.001, 2,500,000,000 shares authorized; 8,602,309 and 8,588,876 issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 9 | 9 | |||||||||
| Additional paid-in capital | 247,574 | 244,285 | |||||||||
| Accumulated deficit | (244,806) | (242,685) | |||||||||
| Accumulated other comprehensive income | 10 | 10 | |||||||||
| Total Stockholders’ Equity | 2,787 | 1,619 | |||||||||
| Total Liabilities and Stockholders’ Equity | $ | 36,605 | $ | 37,343 | |||||||
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||||||||||
| 2026 | 2025 (As Restated) | 2026 | 2025 (As Restated) | ||||||||||||||||||||
| Revenue | $ | 9,739 | $ | 10,054 | $ | 19,358 | $ | 19,387 | |||||||||||||||
| Cost of Revenues | 2,315 | 2,206 | 4,502 | 4,164 | |||||||||||||||||||
| Gross Margin | 7,424 | 7,848 | 14,856 | 15,223 | |||||||||||||||||||
| Operating Expenses: | |||||||||||||||||||||||
| General and administrative | 4,902 | 4,368 | 10,152 | 9,211 | |||||||||||||||||||
| Selling and marketing | 1,923 | 1,674 | 4,322 | 3,205 | |||||||||||||||||||
| Research and development | 628 | 194 | 1,289 | 402 | |||||||||||||||||||
| Depreciation and amortization | 251 | 174 | 497 | 366 | |||||||||||||||||||
| Total Operating Expenses | 7,704 | 6,410 | 16,260 | 13,184 | |||||||||||||||||||
| Operating (Loss) Income | (280) | 1,438 | (1,404) | 2,039 | |||||||||||||||||||
| Other (Expense) Income: | |||||||||||||||||||||||
| Interest expense | (518) | (1,939) | (1,064) | (3,848) | |||||||||||||||||||
| Change in fair value of derivative liabilities | - | 990 | - | (3,911) | |||||||||||||||||||
| Other expense | (77) | (27) | (137) | (28) | |||||||||||||||||||
Other income | 199 | 89 | 490 | 181 | |||||||||||||||||||
| Total Other Expense, net | (396) | (887) | (711) | (7,606) | |||||||||||||||||||
| Net (Loss) Income Before Income Taxes | (676) | 551 | (2,115) | (5,567) | |||||||||||||||||||
| Income tax expense | 6 | - | 6 | - | |||||||||||||||||||
| Net (Loss) Income | $ | (682) | $ | 551 | $ | (2,121) | $ | (5,567) | |||||||||||||||
| (Loss) Earnings per Share: | |||||||||||||||||||||||
| Basic | $ | (0.08) | $ | 0.06 | $ | (0.25) | $ | (0.65) | |||||||||||||||
| Diluted | $ | (0.08) | $ | (0.04) | $ | (0.25) | $ | (0.65) | |||||||||||||||
| Weighted average shares outstanding | |||||||||||||||||||||||
| Basic | 8,601,198 | 8,561,737 | 8,596,148 | 8,554,706 | |||||||||||||||||||
| Diluted | 8,601,198 | 9,167,846 | 8,596,148 | 8,554,706 | |||||||||||||||||||
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
(In thousands, except share data)
| Three Months Ended June 30, 2026 | ||||||||||||||||||||||||||||||||||||||
| Common Stock | ||||||||||||||||||||||||||||||||||||||
| Number of Shares Issued and Outstanding | Par Value | Additional Paid- in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income | Total | |||||||||||||||||||||||||||||||||
| Balances as of March 31, 2026 | 8,594,209 | $ | 9 | $ | 245,943 | $ | (244,124) | $ | 10 | $ | 1,838 | |||||||||||||||||||||||||||
| Stock-based compensation | - | - | 1,403 | - | - | 1,403 | ||||||||||||||||||||||||||||||||
| Stock options exercised | 4,100 | - | 58 | - | - | 58 | ||||||||||||||||||||||||||||||||
| Shares issued for services rendered | 4,000 | - | 67 | - | - | 67 | ||||||||||||||||||||||||||||||||
| Shares granted in lieu of board of director fees | - | - | 102 | - | - | 102 | ||||||||||||||||||||||||||||||||
Net loss | - | - | - | (682) | - | (682) | ||||||||||||||||||||||||||||||||
| Balances as of June 30, 2026 | 8,602,309 | $ | 9 | $ | 247,574 | $ | (244,806) | $ | 10 | $ | 2,787 | |||||||||||||||||||||||||||
| Three Months Ended June 30, 2025 | ||||||||||||||||||||||||||||||||||||||
| Common Stock | ||||||||||||||||||||||||||||||||||||||
| Number of Shares Issued and Outstanding | Par Value | Additional Paid- in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income | Total | |||||||||||||||||||||||||||||||||
| Balances as of March 31, 2025 (As Restated) | 8,548,473 | $ | 9 | $ | 239,786 | $ | (260,617) | $ | 10 | $ | (20,812) | |||||||||||||||||||||||||||
| Stock-based compensation | - | - | 1,132 | - | - | 1,132 | ||||||||||||||||||||||||||||||||
| Stock options exercised | 17,008 | - | 253 | - | - | 253 | ||||||||||||||||||||||||||||||||
| Shares granted in lieu of board of director fees | 2,524 | - | 77 | - | - | 77 | ||||||||||||||||||||||||||||||||
Net income (As Restated) | - | - | - | 551 | - | 551 | ||||||||||||||||||||||||||||||||
| Balances as of June 30, 2025 (As Restated) | 8,568,005 | $ | 9 | $ | 241,248 | $ | (260,066) | $ | 10 | $ | (18,799) | |||||||||||||||||||||||||||
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
(In thousands, except share data)
| Six Months Ended June 30, 2026 | ||||||||||||||||||||||||||||||||||||||
| Common Stock | ||||||||||||||||||||||||||||||||||||||
| Number of Shares Issued and Outstanding | Par Value | Additional Paid- in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income | Total | |||||||||||||||||||||||||||||||||
| Balances as of December 31, 2025 | 8,588,876 | $ | 9 | $ | 244,285 | $ | (242,685) | $ | 10 | $ | 1,619 | |||||||||||||||||||||||||||
| Stock-based compensation | - | 2,842 | - | - | 2,842 | |||||||||||||||||||||||||||||||||
| Stock options exercised | 5,433 | - | 77 | - | - | 77 | ||||||||||||||||||||||||||||||||
| Shares issued for services rendered | 8,000 | - | 164 | - | - | 164 | ||||||||||||||||||||||||||||||||
| Shares granted in lieu of board of director fees | - | - | 205 | - | - | 205 | ||||||||||||||||||||||||||||||||
| Net loss | - | - | - | (2,121) | - | (2,121) | ||||||||||||||||||||||||||||||||
| Balances as of June 30, 2026 | 8,602,309 | $ | 9 | $ | 247,574 | $ | (244,806) | $ | 10 | $ | 2,787 | |||||||||||||||||||||||||||
| Six Months Ended June 30, 2025 | ||||||||||||||||||||||||||||||||||||||
| Common Stock | ||||||||||||||||||||||||||||||||||||||
| Number of Shares Issued and Outstanding | Par Value | Additional Paid- in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income | Total | |||||||||||||||||||||||||||||||||
| Balance as of December 31, 2024 (As Restated) | 8,543,686 | $ | 9 | $ | 238,685 | $ | (254,499) | $ | 10 | $ | (15,795) | |||||||||||||||||||||||||||
| Stock-based compensation | 4,787 | - | 2,233 | - | - | 2,233 | ||||||||||||||||||||||||||||||||
| Stock options exercised | 17,008 | - | 253 | - | - | 253 | ||||||||||||||||||||||||||||||||
| Shares granted in lieu of board of director fees | 2,524 | - | 77 | - | - | 77 | ||||||||||||||||||||||||||||||||
| Net loss (As Restated) | - | - | - | (5,567) | - | (5,567) | ||||||||||||||||||||||||||||||||
| Balances as of June 30, 2025 (As Restated) | 8,568,005 | $ | 9 | $ | 241,248 | $ | (260,066) | $ | 10 | $ | (18,799) | |||||||||||||||||||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Six Months Ended June 30, | |||||||||||
(in thousands) | 2026 | 2025 (As Restated) | |||||||||
| Operating Activities: | |||||||||||
| Net loss | $ | (2,121) | $ | (5,567) | |||||||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities | |||||||||||
| Stock-based compensation | 3,143 | 2,106 | |||||||||
| Depreciation and amortization | 607 | 388 | |||||||||
| Amortization of right-of-use leases | 56 | 185 | |||||||||
| Provision for credit losses | 379 | 131 | |||||||||
| Change in fair value of derivative liabilities | - | 3,911 | |||||||||
| Amortization of debt issuance and debt discounts | 111 | 1,062 | |||||||||
| Write-off of inventory | 69 | - | |||||||||
| Loss on disposal of assets | 18 | - | |||||||||
| Proceeds from tenant improvement funds | - | 429 | |||||||||
| Changes in operating assets and liabilities | |||||||||||
| Accounts receivable | (757) | (650) | |||||||||
| Inventory | (1,205) | (1,762) | |||||||||
| Prepaid expenses and other assets | 385 | (1,231) | |||||||||
| Accounts payable | (133) | 274 | |||||||||
| Accrued expenses and contract liabilities | 370 | 200 | |||||||||
| Operating leases | (100) | - | |||||||||
| Net Cash Provided by (Used in) Operating Activities | 822 | (524) | |||||||||
| Investing Activities | |||||||||||
Purchase of property and equipment | (357) | (1,321) | |||||||||
| Deposits on property and equipment | (35) | - | |||||||||
| Investment in software development | (213) | - | |||||||||
| Net Cash Used in Investing Activities | (606) | (1,321) | |||||||||
| Financing Activities | |||||||||||
| Proceeds from exercises of stock options | 77 | 253 | |||||||||
| Repayment of principal secured term loan | (2,875) | - | |||||||||
| Payments of principal on finance leases | - | (149) | |||||||||
| Net Cash (Used in) Provided by Financing Activities | (2,798) | 104 | |||||||||
| Net Change in Cash During Period | (2,583) | (1,741) | |||||||||
Cash at Beginning of Period | 11,959 | 10,237 | |||||||||
Cash at End of Period | $ | 9,376 | $ | 8,496 | |||||||
| Supplemental Information: | |||||||||||
| Cash paid for interest | $ | 828 | $ | 2,255 | |||||||
| Cash paid for income taxes | $ | 51 | $ | - | |||||||
| Non-cash Investing and Financing Activities: | |||||||||||
| Right-of-use assets obtained in exchange for lease liabilities | 619 | 430 | |||||||||
| Stock options granted in lieu of cash bonus | 69 | 117 | |||||||||
| Purchases of property and equipment in accounts payable | 191 | - | |||||||||
| Capitalize interest into senior secured debt | - | 407 | |||||||||
| RSUs granted in exchange for services | - | 10 | |||||||||